Towards Multidrug Adaptive Therapy
暂无分享,去创建一个
Li You | Alexander R A Anderson | Robert A Gatenby | Paul K Newton | Jeffrey West | Joel S Brown | Jingsong Zhang | Joel s. Brown | R. Gatenby | P. Newton | Jingsong Zhang | A. Anderson | J. West | Li You
[1] Camille Stephan-Otto Attolini,et al. Evolutionary Theory of Cancer , 2009, Annals of the New York Academy of Sciences.
[2] Ville Mustonen,et al. Predicting evolution , 2017, Nature Ecology &Evolution.
[3] A. Deutsch,et al. Studying the emergence of invasiveness in tumours using game theory , 2008, 0810.4724.
[4] David Basanta,et al. Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer , 2017, Nature Ecology & Evolution.
[5] P. Majumder,et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.
[6] K. Pienta,et al. Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.
[7] T. Vincent,et al. Lessons from applied ecology: cancer control using an evolutionary double bind. , 2009, Cancer research.
[8] A. Jackson,et al. The mutation rate and cancer. , 1998, Genetics.
[9] J. Fletcher. Evolutionary Game Theory, Natural Selection, and Darwinian Dynamics , 2006, Journal of Mammalian Evolution.
[10] J. Salk. Clonal evolution in cancer , 2010 .
[11] S. Schuster,et al. Evolutionary game theory: cells as players. , 2014, Molecular bioSystems.
[12] Robert A Gatenby,et al. Application of Evolutionary Principles to Cancer Therapy. , 2015, Cancer research.
[13] David Basanta,et al. Homeostasis Back and Forth: An Eco-Evolutionary Perspective of Cancer , 2016, bioRxiv.
[14] M. Perry. The Chemotherapy Source Book , 1992, Annals of Internal Medicine.
[15] C. Maley,et al. Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .
[16] Robert Axelrod,et al. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. , 2008, Translational oncology.
[17] Robert A. Gatenby,et al. Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. , 2018, Journal of theoretical biology.
[18] M. Gerlinger,et al. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.
[19] Michael F. Brown. Forum: On Resisting Resistance , 1996 .
[20] John Vontas,et al. Country-level operational implementation of the Global Plan for Insecticide Resistance Management , 2013, Proceedings of the National Academy of Sciences.
[21] Folco Giomi,et al. Nothing in experimental biology makes sense except in the light of ecology and evolution – correspondence on J. Exp. Biol. 216, 2771-2782 , 2013, Journal of Experimental Biology.
[22] Krishnendu Chatterjee,et al. Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.
[23] R. Gadagkar. Nothing in Biology Makes Sense Except in the Light of Evolution , 2005 .
[24] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[25] Carlo C. Maley,et al. Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research , 2011, PloS one.
[26] C. Sima,et al. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[28] Robert Noble,et al. Spatial competition constrains resistance to targeted cancer therapy , 2017, Nature Communications.
[29] A. Deutsch,et al. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion , 2008, Cell proliferation.
[30] B. Frieden,et al. Adaptive therapy. , 2009, Cancer research.
[31] Nick Jagiella,et al. Estimating Dose Painting Effects in Radiotherapy: A Mathematical Model , 2014, PloS one.
[32] Jeffrey West,et al. The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory. , 2019, JCO clinical cancer informatics.
[33] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[34] Robert A. Gatenby,et al. Optimizing Cancer Treatment Using Game Theory: A Review , 2019, JAMA oncology.
[35] Rebecca Ryan,et al. Analysis of after-action reporting by deployed nurses. , 2008, Military medicine.
[36] A. Liebman,et al. Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions , 1998, Annals of Internal Medicine.
[37] Joel s. Brown,et al. Classifying the evolutionary and ecological features of neoplasms , 2017, Nature Reviews Cancer.
[38] Alexander Lorz,et al. Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. , 2015, Cancer research.
[39] Robert A Gatenby,et al. Evolutionary Strategy for Systemic Therapy of Metastatic Breast Cancer: Balancing Response with Suppression of Resistance , 2014, Women's health.
[40] Robert A. Gatenby,et al. Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy , 2019, Clinical Cancer Research.
[41] Franziska Michor,et al. Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..
[42] David Basanta,et al. Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2011, Molecular pharmaceutics.
[43] Joel s. Brown,et al. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer , 2017, Nature Communications.
[44] Robert J Woods,et al. How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient , 2017, PLoS biology.
[45] B. Foth,et al. Resisting resistance , 2012, Nature Reviews Microbiology.
[46] Joel s. Brown,et al. Why Darwin would have loved evolutionary game theory , 2016, Proceedings of the Royal Society B: Biological Sciences.
[47] Frank Thuijsman,et al. Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model. , 2017, Journal of theoretical biology.
[48] David Basanta,et al. Exploiting ecological principles to better understand cancer progression and treatment , 2013, Interface Focus.
[49] Jeffrey West,et al. Capitalizing on Competition: An Evolutionary Model of Competitive Release in Metastatic Castrate Resistant Prostate Cancer Treatment , 2017, bioRxiv.
[50] P K Newton,et al. Nonlinear adaptive control of competitive release and chemotherapeutic resistance. , 2019, Physical review. E.
[51] Robert A Gatenby,et al. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies , 2017, bioRxiv.
[52] Christa-Marie Singleton,et al. An analysis of root cause identification and continuous quality improvement in public health H1N1 after-action reports. , 2014, Journal of public health management and practice : JPHMP.
[53] Ville Mustonen,et al. The value of monitoring to control evolving populations , 2014, Proceedings of the National Academy of Sciences.
[54] T. Dobzhansky. Nothing in Biology Makes Sense Except in the Light of Evolution , 1973 .
[55] Goldie Jh,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .
[56] Janet Hemingway,et al. Implementation of the global plan for insecticide resistance management in malaria vectors: progress, challenges and the way forward , 2015, Malaria Journal.
[57] David Liao,et al. Conceptualizing a tool to optimize therapy based on dynamic heterogeneity , 2012, Physical biology.
[58] Chen-Hsiang Yeang,et al. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.
[59] J H Goldie,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.
[60] Yang Kuang,et al. Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. , 2014, Cancer research.
[61] R. Gillies,et al. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.
[62] Stephanie Forrest,et al. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.